Genmab has initiated a Phase III study with HuMax-CD20 to treat patients with refractory B-cell Chronic Lymphocytic Leukemia (CLL). HuMax-CD20 received a Fast Track designation from the FDA in December 2004 for this indication. The study will include approximately 100 CLL patients who have failed treatment with fludarabine and alemtuzumab or who have failed fludarabine and are intolerant to or ineligible for alemtuzumab. Patients in the single arm trial will receive eight weekly infusions o...